An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson’s and Alzheimer’s result from a large spectrum of biological abnormalities, hampering effective treatment.
Acclaimed neurologist Dr Alberto Espay and Parkinson’s advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson’s or Alzheimer’s, simply people with Parkinson’s or Alzheimer’s. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track.
Dr. Nilüfer Ertekin-Taner, neurogeneticist and behavioral neurologist, discusses characteristics of neurodegenerative diseases such as dementia, Alzheimer’s disease, and movement disorders. She also discusses her research on the complex genetics of Alzheimer’s disease, including identifying therapeutic targets and biomarkers. She highlights Mayo Clinic’s unique approach to patient care.
Parkinson’s disease is a neurological condition that affects the brain and other parts of the nervous system. The gradual loss of nerve cells leads to a suite of characteristic motor and non-motor symptoms.
What causes these cells to die and how the pathology develops in the nervous system are not yet clear but multiple lines of investigation are being pursued to answer these questions. In this animation, we explore some of the latest in Parkinson’s disease research.
From a Neuroscience News & Research online article:
“The link between antibiotic exposure and Parkinson’s disease fits the current view that in a significant proportion of patients the pathology of Parkinson’s may originate in the gut, possibly related to microbial changes, years before the onset of typical Parkinson motor symptoms such as slowness, muscle stiffness and shaking of the extremities. It was known that the bacterial composition of the intestine in Parkinson’s patients is abnormal, but the cause is unclear. Our results suggest that some commonly used antibiotics, which are known to strongly influence the gut microbiota, could be a predisposing factor,” says research team leader, neurologist Filip Scheperjans MD, Ph.D. from the Department of Neurology of Helsinki University Hospital.
Higher exposure to commonly used oral antibiotics is linked to an increased risk of Parkinson’s disease according to a recently published study by researchers from the Helsinki University Hospital, Finland.
The strongest associations were found for broad-spectrum antibiotics and those that act against anaerobic bacteria and fungi. The timing of antibiotic exposure also seemed to matter.
The study suggests that excessive use of certain antibiotics can predispose to Parkinson’s disease with a delay of up to 10 to 15 years. This connection may be explained by their disruptive effects on the gut microbial ecosystem.